PMID- 32921782
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Print)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Sep 7
TI  - The clinical application of metformin in children and adolescents: A short 
      update.
PG  - e2020086
LID - 10.23750/abm.v91i3.10127 [doi]
AB  - Metformin is a widely used drug that results in clear benefits in relation to 
      glucose metabolism and diabetes-related complications. The global increase in the 
      prevalence of obesity among children and adolescents is accompanied by the 
      appearance and increasing prevalence of insulin resistance, prediabetes, and type 
      2 diabetes mellitus (T2DM). In addition, children, and adolescents with premature 
      pubarche and polycystic ovary have considerable degree of insulin resistance. The 
      insulin sensitizing actions of metformin encouraged many investigators and 
      physician to use it as the key drug in these conditions for both prevention and 
      treatment. However, long term-controlled studies are still required to assess the 
      degree and duration of effectiveness and safety of using metformin. This review 
      tries to update physicians about the main and the new therapeutic perspectives of 
      this drug.
FAU - Soliman, Ashraf
AU  - Soliman A
AD  - Department of Pediatrics, Division of Endocrinology, Hamad General Hospital, 
      Doha, Qatar. atsoliman56@gmail.com.
FAU - De Sanctis, Vincenzo
AU  - De Sanctis V
AD  - Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy. 
      vdesanctis@libero.it.
FAU - Alaaraj, Nada
AU  - Alaaraj N
AD  - Department of Pediatrics, Division of Endocrinology, Hamad General Hospital, 
      Doha, Qatar. vdesanctis@libero.it.
FAU - Hamed, Noor
AU  - Hamed N
AD  - Department of Pediatrics, Division of Endocrinology, Hamad General Hospital, 
      Doha, Qatar. vdesanctis@libero.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200907
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Insulin Resistance
MH  - *Metformin/therapeutic use
MH  - *Polycystic Ovary Syndrome/drug therapy
PMC - PMC7717009
COIS- Each author declares that he or she has no commercial associations (e.g. 
      consultancies, stock ownership, equity interest, patent/licensing arrangement 
      etc.) that might pose a conflict of interest in connection with the submitted 
      article
EDAT- 2020/09/15 06:00
MHDA- 2021/06/29 06:00
PMCR- 2020/01/01
CRDT- 2020/09/14 05:47
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/09/14 05:47 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - ACTA-91-86 [pii]
AID - 10.23750/abm.v91i3.10127 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Sep 7;91(3):e2020086. doi: 10.23750/abm.v91i3.10127.